News | June 25, 2026
Shilpa Medicare subsidiary settles Rs. 20.13 crore dispute with Sartorius for Rs. 9 crore
The resolution significantly reduces a long-standing contingent liability from the company's books
The resolution significantly reduces a long-standing contingent liability from the company's books
Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support
Paves way for CNS cancer test rollout
The hospital chain reported strong growth driven by its Gurugram facility, international patient inflow, and operational efficiencies
Veteran pharma leader brings 33+ years of experience to drive operational excellence in formulation business
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
Subscribe To Our Newsletter & Stay Updated
